BACKGROUND Neutralizing antibodies are considered a key correlate of protection by
current SARS-CoV-2 vaccines. The manner in which human infections respond to therapeutic …

Determination of SARS-CoV-2 antibody responses in the context of pre-existing immunity to
circulating human coronavirus (HCoV) is critical for understanding protective immunity. Here …

Vaccines against SARS-CoV-2 have been rapidly approved. Although pivotal studies were
conducted in healthy volunteers, little information is available on the safety and efficacy of …

Extension of the COVERALL (COrona VaccinE tRiAL pLatform) randomized trial showed
noninferiority in antibody response of the third dose of Moderna mRNA-1273 vaccine (95.3% […

Background Serological data on endemic human coronaviruses (HCoVs) and severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) in southern Africa are scarce. Here, we …

Objectives: This study aimed to investigate the association of demographic and clinical
characteristics, including HIV-specific parameters with the antibody response to a third dose of a …

Allogeneic haematopoietic cell transplantation (allo‐HCT) recipients show impaired
antibody (Ab) response to a standard two‐dose vaccination against severe acute respiratory …

Objectives To correlate immune responses following a two-dose regimen of mRNA anti-SARS-CoV-2
vaccines in patients with rheumatoid arthritis (RA) to the development of a potent …

Numerous clinical parameters link to severe coronavirus disease 2019, but factors that
prevent symptomatic disease remain unknown. We investigated the impact of severe acute …

Background Factors influencing susceptibility to severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) remain to be resolved. Using data from the Swiss HIV Cohort Study on …